MedTrace Logo

Dual Vaccine Trial in Myeloproliferative Neoplasms

NCT04051307 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-07-13

No results posted yet for this study

Summary

A phase I-II study in patients with mutated MPN by vaccinating with PD-L1 and Aginase1 peptides with Montanide ISA-51 as adjuvant, to monitor the immunological response to vaccination and subsequently safety, toxicity and clinical effect.

Conditions

Interventions

DRUG

PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL

Peptide vaccination

DRUG

Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL

Peptide vaccination

Sponsors & Collaborators

  • Inge Marie Svane

    lead OTHER

Principal Investigators

  • Jacob H Grauslund, MD · CENTER FOR CANCER IMMUNE THERAPY, CCIT-DK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-10
Primary Completion
2022-07-10
Completion
2022-07-10

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04051307 on ClinicalTrials.gov